SJD Barcelona Children’s Hospital
SJD Barcelona Children’s Hospital
Hiszpania, Barcelona
Tylko dzieci i młodzież (0-18 lat)
Jaume Mora Graupera
30 lat doświadczenia
akredytacje :
Akredytacje :
The Ewing's sarcoma treatment cost in Spain typically involves a PET-CT scan ranging from $1,300 to $1,800 and complex treatment plans costing $35,000 to $65,000. Total expenses depend on the stage, the need for limb-preserving surgery, and the clinic tier. Patients often save approximately 78–84% compared to the United States. Key medical hubs include Barcelona and Madrid.
Typical Ewing's Sarcoma Treatment Costs in Spain
Bookimed Expert Insight: Pediatric patients benefit most from specialized centers. SJD Barcelona Children’s Hospital is a top-three European pediatric facility. It offers advanced molecular diagnostics for precise tailoring of Ewing's sarcoma protocols. For adult cases, Centro Médico Teknon provides JCI-accredited care. They utilize robotized surgeries and PET-CT imaging for highly accurate tumor staging. Patients seeking clinical trials should consider Quironsalud Madrid. They integrate innovative cancer research directly into patient care plans.
Dr Graupera jest uznanym onkologiem dziecięcym, specjalizującym się w mięsakach kości i tkanek miękkich w Szpitalu Dziecięcym Sant Joan de Déu w Barcelonie — jednym z czołowych ośrodków pediatrycznych w Europie.
Dr Blanca Lopez Ibor kieruje Oddziałem Hematologii i Onkologii Dziecięcej w sieci szpitali HM Hospitales, posiadając ponad 30-letnie doświadczenie w onkologii dziecięcej.
Od ponad 20 lat specjalizuje się w onkologii dziecięcej — dr López-Ibor kieruje Oddziałem Hematologii i Onkologii Dziecięcej w HM Montepríncipe.
Lekarz jest wybitnym onkologiem medycznym z ponad 30-letnim doświadczeniem, specjalizującym się w niechirurgicznym leczeniu nowotworów układu moczowo-płciowego, w tym raka prostaty, nerek i pęcherza moczowego, a także mięsaków i guzów o nieznanym pochodzeniu. Obecnie lekarz kieruje Oddziałem Nowotworów Układu Moczowo-Płciowego, Centralnego Układu Nerwowego, Mięsaków i Guzów o Nieznanym Pochodzeniu w Szpitalu Uniwersyteckim Vall d'Hebron w Barcelonie i współpracuje z Centrum Medycznym Teknon.<\/p>
Posiadając doktorat z medycyny i chirurgii, lekarz prowadził liczne krajowe wieloośrodkowe badania kliniczne i jest autorem ponad 120 recenzowanych artykułów. Lekarz jest uznawany za jednego z czołowych ekspertów w Hiszpanii w dziedzinie onkologii układu moczowo-płciowego.<\/p>
Spain hosts several leading centers for Ewing's sarcoma, specializing in limb-preservation and pediatric oncology. SJD Barcelona Children's Hospital and Clínica Universidad de Navarra are primary choices. These institutions use multidisciplinary tumor boards and advanced biological reconstructions. They maintain high survival and limb-retention rates for complex bone tumors.
Bookimed Expert Insight: While SJD Barcelona is a top choice for children, adult patients often find better multidisciplinary support at Centro Médico Teknon or Quironsalud Madrid. These centers manage higher volumes of adult musculoskeletal cases and offer genomic profiling for targeted therapy. Interestingly, Bookimed data shows that centers in Barcelona like Hospital Quiron Barcelona often collaborate with American oncology institutions, providing access to international treatment protocols that may not be available in smaller regional hospitals.
Patient Consensus: Patients emphasize finding a hospital with a dedicated sarcoma team rather than a general oncology ward. They note that having pathology, imaging, and surgery coordinated in one system is vital for accurate diagnosis and timely treatment.
Leading Ewing's sarcoma specialists in Spain include Dr. Jaume Mora Graupera at SJD Barcelona Children's Hospital and Dr. Blanca Lopez Ibor at HM Hospitales. These experts operate within JCI-accredited facilities. They provide integrated care involving molecular diagnostics, chemotherapy, and limb-preserving surgery for pediatric and adult patients.
Bookimed Expert Insight: Spain's high-volume centers provide a distinct advantage for rare bone tumors. SJD Barcelona Children's Hospital performs 14,000 operations annually and houses a dedicated Molecular Medicine Laboratory. This infrastructure allows specialists to refine treatment protocols based on specific genetic markers. It often leads to higher success rates in complex limb-sparing procedures.
Patient Consensus: Patients emphasize the need for expert pathology reviews before starting any treatment. They advocate for care at major university hospitals in Madrid or Barcelona where surgery and radiation are managed together.
Standard first-line therapy for Ewing's sarcoma in Spain involves a multi-modal approach of induction chemotherapy, surgery, and radiation. Spanish oncology centers utilize European protocols, treating the condition as a systemic disease. Centers like SJD Barcelona Children's Hospital use molecular diagnostics to guide these intensive protocols.
Bookimed Expert Insight: Spanish pediatric centers show a heavy concentration of expertise in Barcelona. Dr. Jaume Mora Graupera at SJD Barcelona Children's Hospital brings specialized training from Memorial Sloan Kettering. This transatlantic experience often means Spanish protocols incorporate both leading European research and North American surgical techniques.
Patient Consensus: Patients note that chemotherapy starts immediately to treat the whole body. They found the decision between surgery or radiation depends strictly on the tumor's location.
Advanced therapies like CAR-T cell and targeted drugs are available in Spain. The country serves as a major European hub for oncology. Patients access these treatments through a network of accredited centers. Implementation relies on specific genetic profiles or clinical trial eligibility.
Bookimed Expert Insight: Spain’s unique hospital exemption model allows centers like SJD Barcelona Children's Hospital to develop academic CAR-T therapies on-site. This significantly increases availability beyond commercial drugs. Note that HLA-matching or specific molecular reports are required before specialists can confirm eligibility for these programs.
Patient Consensus: Patients emphasize that reaching a dedicated sarcoma team in Barcelona or Madrid is vital for accessing experimental options. They note that bringing complete pathology and molecular reports helps speed up the specialist review process.
Treatment for Ewing's sarcoma in Spain typically spans 6 to 12 months. This multi-phase process includes intensive chemotherapy cycles followed by local control measures like surgery or radiation. Specialized centers often perform bone resections and utilize molecular diagnostics to tailor the timeline for each case.
Bookimed Expert Insight: Spanish centers like SJD Barcelona Children's Hospital and HM Madrid specialize in highly complex pediatric cases. Data shows these institutions often use a Molecular Medicine Laboratory to refine protocols. This can adjust the treatment timeframe based on how the specific tumor responds to the first chemotherapy cycles. Patients should prioritize clinics with dedicated internal molecular labs to ensure the treatment schedule remains as efficient as possible.
Patient Consensus: Patients note that treatment is a prolonged commitment that requires clear phase-by-phase scheduling. They emphasize the importance of identifying which team coordinates the transition from chemotherapy to specialized surgery.
Spanish hospitals provide language and translation assistance through tele-translation systems and international patient departments. JCI-accredited facilities often employ multilingual coordinators for foreign patients. While most doctors speak professional English, nursing and administrative staff may have limited proficiency outside major medical hubs.
Bookimed Expert Insight: Data shows that choosing a major pediatric center like SJD Barcelona Children's Hospital is vital for Ewing's sarcoma. These high-volume institutions treat 450,000 patients annually and have more robust systems for international families than general hospitals. Their teams are accustomed to managing complex oncological communication for rare cases.
Patient Consensus: Patients note that while doctors communicate well in English, ward nurses often do not, making a bilingual advocate helpful. It is essential to confirm in advance if pathology results and consent forms can be provided in English.